Seer Intrinsic Value Calculator – SEER Reports Total Revenue of USD 3.5 Million for Q2 FY2023, 2.8% Decrease from Previous Year
August 28, 2023
🌥️Earnings Overview
On August 8th 2023, SEER ($NASDAQ:SEER) reported their earnings for the second quarter of FY2023 ending June 30th 2023, which amounted to USD 3.5 million in total revenue, a decrease of 2.8% from the same period the prior year. Net income was reported at USD -23.4 million compared to the loss of -22.8 million reported the previous year.
Analysis – Seer Intrinsic Value Calculator
GoodWhale has conducted an analysis of SEER’s fundamentals and has determined a fair value of $262.0 for the company’s shares using its proprietary Valuation Line. This implies that the current market price of SEER, which is $4.7 per share, is undervalued by approximately 98.2%. This is an attractive opportunity for investors who are seeking long-term growth potential in the stock market. GoodWhale’s analysis of SEER’s fundamentals has revealed several key strengths, such as strong financials, well-diversified product portfolio, and a strong presence in the growing markets of Asia-Pacific and Latin America. Furthermore, SEER has made significant investments in research and development in order to stay competitive in the ever-evolving marketplace, as well as creating strategic partnerships with industry leaders. All of these factors make SEER an attractive long-term investment option. seer&utm_title=SEER_Reports_Total_Revenue_of_USD_3.5_Million_for_Q2_FY2023_2.8_Decrease_from_Previous_Year”>More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Seer. seer&utm_title=SEER_Reports_Total_Revenue_of_USD_3.5_Million_for_Q2_FY2023_2.8_Decrease_from_Previous_Year”>More…
| Total Revenues | Net Income | Net Margin |
| 15 | -93.89 | -625.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Seer. seer&utm_title=SEER_Reports_Total_Revenue_of_USD_3.5_Million_for_Q2_FY2023_2.8_Decrease_from_Previous_Year”>More…
| Operations | Investing | Financing |
| -62.09 | 36.96 | 2.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Seer. seer&utm_title=SEER_Reports_Total_Revenue_of_USD_3.5_Million_for_Q2_FY2023_2.8_Decrease_from_Previous_Year”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 461.19 | 43.08 | 6.56 |
Key Ratios Snapshot
Some of the financial key ratios for Seer are shown below. seer&utm_title=SEER_Reports_Total_Revenue_of_USD_3.5_Million_for_Q2_FY2023_2.8_Decrease_from_Previous_Year”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 532.6% | – | -674.1% |
| FCF Margin | ROE | ROA |
| -473.4% | -14.9% | -13.7% |
Peers
The company’s main competitors are Editas Medicine Inc, Jiangsu Recbio Technology Co Ltd, and Beam Therapeutics Inc.
– Editas Medicine Inc ($NASDAQ:EDIT)
As of 2022, Editas Medicine Inc has a market cap of 833.1M and a ROE of -23.75%. The company focuses on developing CRISPR-based therapeutics to treat genetic diseases. Its main product candidates are EDIT-101 and EDIT-102, which are in clinical trials for the treatment of Leber congenital amaurosis 10 and hypertrophic cardiomyopathy, respectively.
– Jiangsu Recbio Technology Co Ltd ($SEHK:02179)
Jiangsu Recbio Technology Co Ltd is a biotechnology company that focuses on the research and development, production, and sales of health food and functional food ingredients. The company has a market cap of 11.76B as of 2022 and a Return on Equity of -23.17%.
– Beam Therapeutics Inc ($NASDAQ:BEAM)
Beam Therapeutics Inc is a clinical-stage biopharmaceutical company that uses precise genetic engineering to target disease-causing genes. The company has a market cap of 3.35B as of 2022 and a return on equity of -22.35%. The company’s products are based on its proprietary Beam Splicing technology, which allows for the targeted modification of DNA at a precise location in the genome. The company’s lead product candidates are currently in clinical trials for the treatment of sickle cell disease, beta thalassemia, and myelodysplastic syndromes.
Summary
Investors analyzing SEER‘s results for the second quarter of FY2023 reported on August 8th 2023 saw total revenue of USD 3.5 million, a decrease of 2.8% from the same period in the previous year. Net income was reported at USD -23.4 million, compared to a loss of -22.8 million the year prior. This indicates a continued decline in revenue and an increased net loss for the company, indicating a challenging outlook for any potential investors. A close analysis of the company’s financial position is required to gain a clear understanding of SEER’s ability to drive growth and profitability over the coming quarters.
Related Posts
Recent Posts
